Using the national infrastructures to solve antimicrobial resistance
June 2 @ 09:00 – 13:00 CEST
The first InfraLife workshop gathers stakeholders in the field of antimicrobial resistance (AMR) for a joint discussion on June 2nd, 2021.
The AMR workshop in June will be followed up by activities during Fall to focus and expand initiatives of relevance identified during initial discussions and the first workshop.
As with other InfraLife initiatives – we invite all interested to reach out and be in touch if you want to hear more and see potential to get involved in activities!
New collaborations advancing science are about gathering cross sectorial experts and stakeholders around a grand challenge, taking a thematic approach and engaging the infrastructures and available technologies in how they can help address the question and be part of the solution to the research challenge at hand. And showing the complementarities of the research infrastructures in this setting.
We plan for other future themes besides AMR, such as lifestyle diseases/ cancer and clean water/ the Baltic Sea, considering life sciences beyond human health including environmental challenges. If you are active in these areas within your organization and see potential for joint efforts, please be in touch. We would love to hear from you and learn about the scientific questions and challenges of particular interest, where you would like to get engaged to jointly explore the potential of the national research infrastructures.
Pia Kinhult, moderator
Olli Kallioniemi, SciLifeLab
Marjolein Thunnissen, MAX IV
Andreas Schreyer, ESS
|Current State of Affairs – What have we learnt and where are we going?
Anders Karlén Uppsala University
| SciLifeLab units and capabilities
Annika Jenmalm-Jensen, SciLifeLab
|Large-scale DNA sequencing and the AMR challenge: examples from CARe
Joakim Larsson, Göteborgs universitet
|Life Science opportunities at MAXIV
Selma Maric MAX IV
|A taste of bio-imaging at MAX IV
Karina Thånell, MAX IV
|Structural Biology at the European Spallation Source
Esko Oksanen, ESS
Susanna Abrahmsén-Alami, AstraZeneca
|Round table discussion
What are the most urgent needs for different stakeholders?
How can different funding streams be utilized for AMR?
How do we ensure a steady flow through all stages of development?
How can the infrastructures be of use in the scientific, diagnostic, regulatory challenges of AMR?
|Conclusions and actionable projects to address gaps in AMR
|End of Meeting